Ingovax ACWY50 mcg/0.5 ml

Indications

Ingovax ACWY is a purified bacterial capsular polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal disease (including meningitis and meningococcemia) caused by Neisseria meningitidis serogroups contained in the specific vaccine formulation (typically A, C, Y and W-135, depending on the product).

• Established/guideline-supported use: Immunization of persons at increased risk of invasive meningococcal disease, including travelers to or residents of areas with hyperendemic or epidemic meningococcal disease (e.g., the African "meningitis belt"), pilgrims traveling to Mecca for Hajj or Umrah (as required by Saudi health regulations), military recruits, and laboratory or industrial workers routinely exposed to N. meningitidis isolates or aerosols.
• Established/guideline-supported use: Persons with functional or anatomic asplenia, or with terminal complement component deficiencies, who are at increased risk of meningococcal disease.
• Outbreak control: Use as part of public health response during confirmed outbreaks or epidemics of meningococcal disease caused by a serogroup covered by the vaccine.
• Adjunct/alternative use: An option where a meningococcal conjugate vaccine is unavailable or not preferred, noting that conjugate vaccines are generally preferred for children, adolescents, and for longer-lasting protection.

Ingovax ACWY does not protect against meningococcal disease caused by serogroups not contained in the vaccine (notably serogroup B, which requires a separate meningococcal B vaccine), nor does it protect against other causes of meningitis.

Each dose of Meningococcal Polysaccharide Vaccine contains purified capsular polysaccharide antigens extracted from Neisseria meningitidis of the serogroups included in the specific formulation (commonly serogroups A, C, Y and W-135, approximately 50 micrograms of each polysaccharide per dose). The vaccine is supplied as a sterile, lyophilized (freeze-dried) powder that is reconstituted with the accompanying sterile diluent (typically sterile water or 0.9% sodium chloride) immediately before use. It does not contain live or attenuated bacteria and cannot cause meningococcal disease.

Ingovax ACWY is a non-conjugated, purified bacterial polysaccharide vaccine used to induce active immunity against invasive disease caused by specific serogroups of Neisseria meningitidis, a gram-negative bacterium responsible for bacterial meningitis and septicemia (meningococcemia). Unlike newer conjugate meningococcal vaccines, Ingovax ACWY stimulates a T-cell-independent immune response, which produces a less durable and less robust immune memory, particularly in young children.

Ingovax ACWY is supplied as a lyophilized powder for reconstitution and is administered as a single subcutaneous injection. It is used mainly for adolescents and adults in specific risk situations (travel, outbreaks, occupational exposure, asplenia) rather than for routine childhood immunization schedules, where conjugate meningococcal vaccines are generally preferred.

Ingovax ACWY belongs to the therapeutic class of bacterial polysaccharide vaccines, specifically the meningococcal vaccines used for active immunoprophylaxis against Neisseria meningitidis.

Pharmacology

Meningococcal Polysaccharide Vaccine works by presenting purified capsular polysaccharide antigens from Neisseria meningitidis to the immune system. The polysaccharide capsule is a major virulence factor that helps the bacterium evade host phagocytosis and complement-mediated killing. Following vaccination, the immune system mounts a B-cell-mediated antibody response directed against these capsular polysaccharides.

Because polysaccharide antigens are T-cell independent, the resulting immune response typically produces predominantly IgM antibodies with lower-affinity, shorter-duration protection, minimal boosting effect on revaccination, and poor immunogenicity in children younger than 2 years, whose immune systems respond weakly to T-cell-independent antigens. Protective antibody levels are generally reached within 7 to 10 days after vaccination but decline over several years, which is why revaccination is recommended for individuals with ongoing risk of exposure.

Ingovax ACWY must be reconstituted with the supplied diluent immediately before administration and given as a subcutaneous (SC) injection, preferably into the outer aspect of the upper arm (deltoid region). It must not be given intravenously, intramuscularly, or intradermally. The reconstituted vaccine should be inspected visually for particulate matter or discoloration before administration and used promptly; any unused reconstituted vaccine should be discarded per product labeling. Ingovax ACWY may be administered at the same time as other vaccines, but at a separate injection site using a separate syringe.

Drug Interactions

• Immunosuppressive therapy (corticosteroids, chemotherapy, radiation therapy, other immunosuppressants): May blunt the immune response to Ingovax ACWY, resulting in a lower or less durable antibody response. Where possible, vaccination should be completed before starting immunosuppressive therapy, or deferred until immune function has recovered.
• Other vaccines: Ingovax ACWY can generally be given concomitantly with other inactivated or live vaccines, but each vaccine should be given with a separate syringe at a separate injection site; concurrent administration has not been shown to significantly alter the immune response to either vaccine in most cases, though formal co-administration data vary by specific vaccine pairing and product.
• Immune globulins/blood products: No clinically significant interaction is established for polysaccharide vaccines (unlike live vaccines, which may require spacing from immune globulin administration).

There are no known clinically significant drug-drug interactions with routine oral or systemic medications.

Side Effects

Very common/common: Local injection site reactions such as pain, redness, and swelling/induration lasting 1-2 days; low-grade fever; headache; malaise; irritability (in children).

Uncommon: Higher fever, chills, myalgia, gastrointestinal upset (nausea, vomiting).

Rare/serious: Immediate hypersensitivity reactions including urticaria and, rarely, anaphylaxis; rare reports of Guillain-Barré syndrome have been temporally associated with polysaccharide meningococcal vaccination, though a definitive causal relationship has not been established. Any signs of severe allergic reaction (difficulty breathing, facial/throat swelling, generalized rash, hypotension) require immediate medical attention.

Pregnancy and Lactation

Data on the use of Ingovax ACWY in pregnancy are limited. As with other inactivated/non-live vaccines, Ingovax ACWY should be used during pregnancy only if clearly needed, such as during an outbreak or unavoidable travel to a high-risk endemic area, and only after the potential benefits and risks are discussed with a physician. Ingovax ACWY is not a live vaccine and is not expected to pose a theoretical risk of the kind associated with live-attenuated vaccines, but routine use in pregnancy without a specific indication is not recommended.

It is not known whether Ingovax ACWY is excreted in human milk. Because many vaccines are considered compatible with breastfeeding, a physician should be consulted to weigh the benefits of vaccination against any theoretical risk before use during lactation.

Precautions and Warnings

• Vaccination with Ingovax ACWY should be deferred in individuals with moderate or severe acute febrile illness until the condition has resolved; a minor illness such as a mild cold without fever is not usually a reason to delay.
• Ingovax ACWY provides protection only against the specific meningococcal serogroups contained in the vaccine formulation and does not protect against all meningococcal serogroups (notably not serogroup B in most formulations) or against other bacterial or viral causes of meningitis.
• As a polysaccharide (non-conjugated) vaccine, Ingovax ACWY generally produces a shorter duration of protective immunity than conjugate meningococcal vaccines, and repeated closely-spaced doses may, in some individuals, result in a diminished (hyporesponsive) antibody response; the appropriate revaccination interval per current guidelines should be followed.
• Appropriate medical treatment and supervision must always be available in case of an anaphylactic reaction following administration.
• Ingovax ACWY should be given with caution in individuals with a bleeding disorder (e.g., thrombocytopenia, on anticoagulant therapy), as subcutaneous injection may cause bleeding or bruising at the injection site.
• As with any vaccine, Ingovax ACWY may not protect 100% of vaccinated individuals.

Overdose

There is no specific information on overdosage with Ingovax ACWY, and it is unlikely to occur given its single-dose administration by a healthcare professional. If a dose greater than recommended is inadvertently administered, the individual should be monitored for signs of an exaggerated local or systemic reaction. Anyone who experiences severe symptoms (such as signs of an allergic reaction, high fever, or difficulty breathing) after receiving Ingovax ACWY should seek immediate medical attention or contact emergency services.

Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze; discard if the vaccine has been frozen. Protect from light. Keep out of reach of children. Once reconstituted, use immediately or within the time specified in the product labeling, and discard any unused portion.

Use in Special Populations

Pediatric: Ingovax ACWY is generally indicated for children 2 years of age and older; safety and efficacy in children younger than 2 years have not been established, and this age group typically responds poorly to polysaccharide antigens. For infants and young children requiring meningococcal protection, a conjugate meningococcal vaccine is generally preferred.

Elderly: Limited specific data exist in elderly populations; the vaccine may be used when indicated by risk (e.g., travel, outbreak exposure), with the general expectation that it is well tolerated, though immune response may be somewhat reduced compared with younger adults.

Immunocompromised individuals (including asplenia and complement deficiency): These individuals are at higher risk of invasive meningococcal disease and are a key target group for vaccination, though the immune response to Ingovax ACWY may be reduced compared with immunocompetent individuals; vaccination should still be offered per guidelines, ideally before elective splenectomy or initiation of immunosuppressive therapy when possible.

Renal/hepatic impairment: No specific dose adjustment is established or required for renal or hepatic impairment, as Ingovax ACWY is not metabolized like a systemic drug.

Ingovax ACWY is administered as a single dose for primary immunization, not as a course of treatment. For individuals with ongoing risk of exposure (e.g., continued travel to endemic regions, persistent asplenia, laboratory exposure), revaccination with a single booster dose is generally recommended every 3 to 5 years, per current national or WHO guidance, to maintain protective antibody levels, since immunity from Ingovax ACWY wanes over time.

Ingovax ACWY is supplied as a sterile lyophilized (freeze-dried) powder that must be reconstituted before use with the sterile diluent supplied by the manufacturer. To reconstitute, the diluent is drawn up and injected into the vial of lyophilized vaccine powder using aseptic technique, then gently swirled (not shaken vigorously) until the powder is fully dissolved, producing a clear, colorless to slightly opalescent solution. The reconstituted vaccine should be inspected for particulate matter or discoloration and, if either is present, should not be used. Once reconstituted, the vaccine should be used promptly, within the time window specified in the product's package insert, and any unused portion should be discarded.

Meningococcal Polysaccharide Vaccine is classified as a bacterial capsular polysaccharide vaccine, within the broader category of meningococcal vaccines used for active immunization against Neisseria meningitidis.

Meningococcal Polysaccharide Vaccine works by delivering purified capsular polysaccharide antigens from specific serogroups of Neisseria meningitidis to the immune system. The immune system recognizes these polysaccharides as foreign antigens and produces serogroup-specific antibodies (predominantly IgM, with lower amounts of IgG) directed against the bacterial capsule. These antibodies are bactericidal and opsonizing, meaning they can directly kill the bacteria in the presence of complement and enhance their clearance by phagocytic cells, thereby reducing the risk of invasive meningococcal disease caused by the covered serogroups.

C

Pediatric Use

Ingovax ACWY is generally indicated for use in children 2 years of age and older who are at increased risk of meningococcal disease (e.g., travel to endemic areas, outbreak exposure, asplenia, complement deficiency). The safety and efficacy of Ingovax ACWY in infants and children younger than 2 years have not been established; this age group generally mounts a poor and short-lived antibody response to polysaccharide antigens due to immunologic immaturity. Children first vaccinated before 4 years of age who remain at high risk may need revaccination sooner (approximately every 2-3 years) than older children and adults, because antibody levels decline more rapidly in this younger age group. Where meningococcal protection is required in young infants or children, a conjugate meningococcal vaccine is generally the preferred alternative.